Antitumour activity of ANG1005, a conjugate between paclitaxel and the new brain delivery vector Angiopep-2.

Régina, A; Demeule, M; Ché, C; Lavallée, I; Poirier, J; Gabathuler, R; Béliveau, R; Castaigne, J-P

Régina, A; Demeule, M; Ché, C; Lavallée, I; Poirier, J; Gabathuler, R; Béliveau, R; Castaigne, J-P.

Affiliation

Régina A; Chemistry Department, Université du Québec à Montréal, Montréal, Québec, Canada.

Br J Pharmacol ; 155(2): 185-97, 2008 Sep.

Article in En | MEDLINE | ID: mdl-18574456

Subject(s)

Antineoplastic Agents, Phytogenic/administration & dosage; Brain Neoplasms/drug therapy; Drug Carriers/metabolism; Drug Delivery Systems; Paclitaxel/administration & dosage; Animals; Antineoplastic Agents, Phytogenic/chemistry; Antineoplastic Agents, Phytogenic/therapeutic use; Brain Neoplasms/prevention & control; Disease Models, Animal; Female; Humans; Male; Mice; Mice, Nude; Neoplasm Transplantation; Paclitaxel/chemistry; Paclitaxel/therapeutic use; Peptides/chemistry; Tumor Cells, Cultured/transplantation; Xenograft Model Antitumor Assays

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Brain Neoplasms / Drug Carriers / Drug Delivery Systems / Paclitaxel / Antineoplastic Agents, Phytogenic Limits: Animals / Female / Humans / Male Language: En Journal: Br J Pharmacol Year: 2008 Document type: Article Affiliation country: Canada

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google